The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer

[1]  B. Thürlimann,et al.  Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer , 2006, British Journal of Cancer.

[2]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[3]  Patrick Nicolas,et al.  Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. , 2004, Cancer research.

[4]  P. Bonnier,et al.  Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. , 2004, International journal of oncology.

[5]  P. Thorpe.  Vascular Targeting Agents as Cancer Therapeutics , 2004, Clinical Cancer Research.

[6]  D. Generali,et al.  Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Leek,et al.  The prognostic role of angiogenesis in breast cancer. , 2001, Anticancer research.

[8]  Shant Kumar,et al.  Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer , 2000, International journal of cancer.

[9]  I. Hampson,et al.  CD 105 antagonizes the inhibitory signaling of transforming growth factor b 1 on human vascular endothelial cells , 1999 .

[10]  T. Powles,et al.  Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma , 1999, Cancer.

[11]  S. Kumar,et al.  Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. , 1999, Cancer research.

[12]  B. Bodey,et al.  Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. , 1998, Anticancer research.

[13]  S. Kumar,et al.  A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.

[14]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.

[15]  A. Lee,et al.  Microvessel quantitation and prognosis in invasive breast carcinoma. , 1992, Human pathology.

[16]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[17]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[18]  J. Massagué,et al.  The transforming growth factor-beta family. , 1990, Annual review of cell biology.